IV Nutrient Therapy
Direct intravenous delivery of vitamins, minerals, and amino acids for rapid absorption and therapeutic dosing beyond oral capacity.
Evidence Summary
IV nutrient therapy delivers vitamins and minerals (e.g., the Myers' cocktail of magnesium, B vitamins and vitamin C, or high-dose intravenous vitamin C) directly into the bloodstream, bypassing the gut. Its clearest rationale is pharmacologic. Oral vitamin C absorption is saturable, so plasma levels plateau around 135-220 umol/L even at maximal oral doses, whereas IV infusion can reach roughly 885 umol/L at 1.25 g and about 13,400 umol/L at 50 g - the millimolar, pro-oxidant range that is unattainable by mouth (Padayatty et al., Ann Intern Med 2004). A controlled pharmacokinetic study found IV vitamin C up to 100 g follows predictable first-order kinetics, clears renally within 24 hours, and was well tolerated (Chen et al., Clin Pharmacokinet 2022). Recent clinical trials are encouraging but preliminary: a 2024 randomized trial in metastatic pancreatic cancer reported that adding high-dose IV ascorbate (75 g three times weekly) to gemcitabine/nab-paclitaxel raised median overall survival to 16 vs 8.3 months (HR 0.46) without added toxicity (Bodeker et al., Redox Biology 2024), and an early-phase bladder-cancer trial showed pathological downstaging with preserved quality of life (Taylor et al., Antioxidants 2026). A 2026 systematic review in trauma and a 2026 oncology review both describe possible benefits alongside low-certainty, heterogeneous evidence and conclude IV vitamin C remains investigational rather than standard care (Patel et al., BMJ Mil Health 2026; Roy et al., Curr Med Chem 2026). For routine wellness, energy or detox indications, rigorous evidence is lacking. Key safety considerations include oxalate load and kidney-stone risk at high doses, fluid and electrolyte shifts, and hemolysis risk in G6PD deficiency - screen renal function and G6PD before high-dose infusions.
Evidence Scale
Mechanism of Action
Intravenous delivery bypasses saturable intestinal transport, achieving plasma nutrient concentrations that oral dosing cannot. For vitamin C this is decisive: oral intake caps plasma near 135-220 umol/L, while IV infusion reaches the millimolar range. At these pharmacologic levels ascorbate acts as a pro-oxidant, generating hydrogen peroxide that is selectively cytotoxic to some tumor cells in vitro; at physiologic levels it is an antioxidant and a cofactor for collagen, carnitine and catecholamine synthesis. Other infusion components (B vitamins, magnesium, glutathione) replete cofactors that support energy metabolism and antioxidant defense. Whether these pharmacologic exposures translate into durable clinical benefit is still being tested in trials.
Who Is This For?
Chronic fatigue, immune support, athletic recovery, nutrient deficiencies, cancer adjunct.
Protocol & Dosing
Dose
Varies by formulation. Common: Vitamin C 25-75g, B-complex, Magnesium, Zinc, Glutathione.
Frequency
Weekly to monthly
Duration
Ongoing or series-based
Protocol Summary
Protocols vary by indication and formulation. The Myers' cocktail blends magnesium, calcium, B-complex, B12 and vitamin C as a slow push or short infusion. High-dose IV vitamin C research protocols use 25-100 g per infusion, commonly two to three times weekly, titrated toward target plasma levels (around 350-400 mg/dL in oncology studies). Baseline renal function and G6PD status should be checked before high-dose vitamin C. At Peak Human, IV therapy is used selectively and monitored, with dosing individualized; it complements rather than replaces evidence-based first-line care. Educational information, not medical advice.
Interactions & Precautions
Contraindications
- Renal insufficiency (high-dose C)
- G6PD deficiency (vitamin C)
- Hemochromatosis
Potential Risks
- •Infection
- •Electrolyte imbalance
- •Kidney stress at high doses
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Customize formulations to individual needs. High-dose vitamin C requires G6PD screening. Consider pairing with NAD+ protocols.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
Route and dose decide what IV vitamin C can do
The strongest case for intravenous nutrient therapy is pharmacologic. Oral vitamin C absorption is saturable, so plasma levels plateau around 135–220 µmol/L even at the maximum tolerated oral dose, while IV infusion bypasses that ceiling and reaches roughly 885 µmol/L at 1.25 g and about 13,400 µmol/L at 50 g — the millimolar range that cannot be reached by mouth (Padayatty et al., Ann Intern Med 2004). A controlled pharmacokinetic study confirmed IV vitamin C up to 100 g follows predictable first-order kinetics, clears through the kidneys within 24 hours, and was well tolerated (Chen et al., Clin Pharmacokinet 2022). Clinical trials are promising but still early: a 2024 randomized trial in metastatic pancreatic cancer found that adding high-dose IV ascorbate (75 g three times weekly) to gemcitabine/nab-paclitaxel raised median overall survival to 16 versus 8.3 months (hazard ratio 0.46) with no added toxicity (Bodeker et al., Redox Biology 2024), and an early-phase bladder-cancer trial reported tumor downstaging with preserved quality of life (Taylor et al., Antioxidants 2026).
A 2026 trauma systematic review and a 2026 oncology review both note possible benefits alongside low-certainty, heterogeneous evidence, concluding IV vitamin C remains investigational rather than standard care; for routine wellness, energy, or "detox" indications rigorous evidence is lacking. Main safety considerations: oxalate load and kidney-stone risk at high doses, fluid and electrolyte shifts, and hemolysis risk in G6PD deficiency — renal function and G6PD should be screened before high-dose infusions. Educational information, not medical advice.
Pharmacokinetics · peak plasma vitamin C · log scale
Why route matters: oral plateaus, IV reaches pharmacologic levels
Source: Padayatty et al., Vitamin C pharmacokinetics: implications for oral and intravenous use, Annals of Internal Medicine, 2004. Oral 1.25 g and IV 1.25 g are measured peak plasma concentrations in healthy volunteers; "Oral max" (220 µmol/L, 3 g every 4 h) and "IV 50 g" (13,400 µmol/L) are pharmacokinetic-model estimates. The dashed line marks ~1 mmol/L, the approximate concentration above which ascorbate exerts pro-oxidant effects studied in laboratory models — reachable only intravenously. Mechanistic pharmacology, not a statement of clinical efficacy.
Related on Peak Human
Optimization
Physician-guided protocols where IV therapy may be used selectively.
Advanced Testing
Renal function and G6PD screening before any high-dose infusion.
NAD+ IV Therapy
A related intravenous longevity protocol.
Liposomal Vitamin C
An oral option when pharmacologic IV dosing isn't the goal.
Energy
A common reason people ask about IV nutrient drips.
Peak Human Brief
Weekly review of new longevity research.
Key references: Vitamin C pharmacokinetics: oral vs intravenous — Ann. Intern. Med. (2004) · Pharmacokinetic evaluation of intravenous vitamin C — Clin. Pharmacokinet. (2022) · IV ascorbate + chemotherapy in metastatic pancreatic cancer (RCT) — Redox Biol. (2024) · IV vitamin C + chemotherapy in bladder cancer (phase Ib/IIa) — Antioxidants (2026) · High-dose vitamin C in trauma: systematic review — BMJ Mil. Health (2026) · Vitamin C in cancer prevention and treatment: review — Curr. Med. Chem. (2026)
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
